Overview
The most important thing to understand about this comparison is that the two routes do not deliver the same molecule.
An injection or infusion delivers NAD+ itself into circulation. Oral products cannot — NAD+ is broken down in the digestive tract rather than absorbed intact — so they deliver precursors instead: smaller molecules the body converts into NAD+ after absorption.
So this is not one substance by two routes. It is NAD+ by one route, and NAD+ building blocks by the other.
| Injection / infusion | Oral precursors (NR, NMN, niacin, nicotinamide) | |
|---|---|---|
| What is delivered | NAD+ itself | Precursors the body converts |
| Absorption step | None — direct to circulation | Digestive absorption, then conversion |
| Effect on blood NAD+ metabolites | Prompt rise | Also raises them — this is well documented for NR |
| Administration | Clinic visit; infusion or injection | At home, daily |
| Immediate sensations | Flushing, nausea, cramping if given quickly | Generally none, except flushing with immediate-release niacin |
| Regulatory status | Compounded; not FDA-approved | Varies by compound — see below |
| Relative cost | Substantially higher | Substantially lower |
What is well documented for both: oral NR raises blood NAD+ metabolites reliably in human studies, and infusion raises them too. What is still being characterized is how the two compare on tissue-level delivery and on clinical outcomes — direct head-to-head human comparisons are limited.
Why oral NAD+ does not work as a route
Worth being precise, because "NAD+ supplements" are widely sold and the label is misleading.
NAD+ is a dinucleotide — a relatively large molecule. It is not absorbed intact across the intestinal wall. Enzymes in the gut break it down into components, which are then absorbed and may be reassembled into NAD+ inside cells.
Which means a capsule labeled NAD+ does not deliver NAD+ to your bloodstream. What it delivers is the breakdown products, which is effectively a less efficient precursor.
The better-designed oral products acknowledge this and supply a precursor directly — nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) most commonly. How the precursors differ from each other.
What each route has behind it
Oral precursors have the more developed human dataset, largely because they are easier to study. Human trials of NR in particular have consistently shown that it raises blood NAD+ metabolite levels — that finding is well replicated. It is also generally well tolerated in those studies. What those trials have been less able to establish is the downstream functional consequence, and that work is ongoing.
Injection and infusion deliver NAD+ directly, which removes the absorption and conversion questions entirely. The human research base is smaller, largely because administered treatments are harder and more expensive to study than capsules. What can be said confidently is that the delivery works as described.
The open question for both is tissue distribution — how much of what is delivered reaches the cells where it is wanted. This is an active research area and it applies to both routes rather than distinguishing them.
The regulatory difference, which is worth knowing
The two routes sit in different places, and neither is straightforward.
Injectable and infusible NAD+ is not an FDA-approved drug product. What is administered is prepared by a compounding pharmacy, which means it is not evaluated by the FDA for safety, effectiveness or batch consistency. The full picture on regulatory status.
Oral precursors vary. Niacin and nicotinamide are established vitamins with defined intake recommendations. NR is marketed as a dietary supplement. NMN has a more complicated position — the FDA has taken the view that it is excluded from the dietary supplement definition because it was authorized for investigation as a new drug, and its availability has been affected accordingly.
Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product.
The practical differences
Beyond the science, the routes differ in ways that decide it for most people.
Convenience. A daily capsule at home versus a clinic appointment. For some people that is the whole decision.
Cost. Oral precursors are substantially cheaper per unit time. What things cost here.
Experience. Infusions produce rate-dependent flushing, nausea and cramping when given quickly. Oral precursors generally produce nothing, with the exception of immediate-release niacin, which causes a pronounced and harmless flush that many people find unpleasant.
Consistency. Daily oral dosing produces a steady input; infusions are episodic.
Supervision. Infusion happens in a clinical setting with monitoring. Oral supplementation happens on your own, which is worth mentioning to whoever manages your care rather than treating as separate from it.
How to think about choosing
Three questions do most of the work.
What are you actually addressing? If it is fatigue or brain fog, the common correctable causes come first — thyroid, ferritin, B12, vitamin D, glucose, sleep. Correcting one of those changes more than either route will. Why that panel matters.
What will you actually keep doing? A daily capsule taken consistently delivers more over a year than an infusion course that is not repeated.
What are you willing to spend, and on what timeframe? These are different commitments with different costs, and being clear about that up front avoids disappointment later.
Frequently asked questions
Is an injection better than a supplement? They deliver different things by different routes — NAD+ itself versus precursors the body converts. Oral NR has the larger human dataset for raising NAD+ metabolites; injection removes the absorption question. Direct comparisons are limited.
Do oral NAD+ supplements work? Products labeled as NAD+ do not deliver NAD+ intact, because it is broken down in the gut. Products supplying precursors such as NR do raise blood NAD+ metabolites in human studies.
Which is safer? Oral precursors have been generally well tolerated in trials. Infusions carry rate-dependent effects and are given under supervision for that reason. Injectable NAD+ is compounded rather than FDA-approved.
Can I do both? People do. It is worth telling whoever manages your care what you are taking rather than treating supplements as separate.
Which is better value? Oral precursors cost substantially less per unit time. Whether that makes them better value depends on what you are trying to achieve.
Where this fits in your plan
The choice is less about which is superior and more about what you are addressing, what you will sustain, and what you want to spend.
And it is more interpretable after a panel than before one — because if a correctable cause turns up, that changes the question entirely. What we check, and what NAD+ therapy involves here.
We measure first. Then we act.
Ready to start your second act?
It starts with measuring, not guessing. A short, clinician-reviewed assessment shows what fits you.
This article is educational and is not medical advice. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. Individual results vary.
